Press coverage about Veracyte (NASDAQ:VCYT) has trended positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Veracyte earned a news impact score of 0.33 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.7466713729572 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Veracyte (NASDAQ:VCYT) traded down $0.14 during trading on Wednesday, reaching $6.25. 40,550 shares of the company traded hands, compared to its average volume of 112,069. The company has a market cap of $225.98, a P/E ratio of -6.87 and a beta of 1.61. Veracyte has a one year low of $5.23 and a one year high of $9.80. The company has a debt-to-equity ratio of 0.68, a current ratio of 4.49 and a quick ratio of 4.04.
Several research analysts recently weighed in on the stock. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $5.40 target price on shares of Veracyte in a report on Thursday, March 1st. BTIG Research set a $13.00 target price on shares of Veracyte and gave the stock a “buy” rating in a report on Monday, November 20th. ValuEngine downgraded shares of Veracyte from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Finally, Zacks Investment Research downgraded shares of Veracyte from a “hold” rating to a “sell” rating in a report on Tuesday, March 6th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the stock. Veracyte currently has an average rating of “Hold” and an average price target of $10.78.
TRADEMARK VIOLATION NOTICE: “Favorable Press Coverage Somewhat Unlikely to Impact Veracyte (VCYT) Share Price” was published by BBNS and is owned by of BBNS. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://baseballnewssource.com/2018/03/14/veracyte-vcyt-earns-media-impact-score-of-0-33/1925031.html.
Veracyte, Inc is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.